Invention Grant
- Patent Title: Methods for treating cancer with bispecific anti-CD3xMUC16 antibodies and anti-PD-1 antibodies
-
Application No.: US16447067Application Date: 2019-06-20
-
Publication No.: US11254752B2Publication Date: 2022-02-22
- Inventor: Alison Crawford
- Applicant: Regeneron Pharmaceuticals, Inc.
- Applicant Address: US NY Tarrytown
- Assignee: Regeneron Pharmaceuticals, Inc.
- Current Assignee: Regeneron Pharmaceuticals, Inc.
- Current Assignee Address: US NY Tarrytown
- Agency: Schwabe, Williamson & Wyatt PC
- Agent Veronica Mallon
- Main IPC: C07K16/30
- IPC: C07K16/30 ; A61P35/00 ; A61K39/395 ; A61K45/06 ; C07K16/28 ; C07K16/46 ; A61K39/00
Abstract:
The present invention provides methods for treating, reducing the severity, or inhibiting the growth of cancer (e.g., ovarian cancer or pancreatic cancer). The methods of the present invention comprise administering to a subject in need thereof a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds to programmed death 1 (PD-1) receptor in combination with a therapeutically effective amount of a bispecific antibody that specifically binds Mucin 16 (MUC16) and CD3.
Public/Granted literature
- US20190389966A1 Methods for Treating Cancer with Bispecific Anti-CD3xMUC16 Antibodies and Anti-PD-1 Antibodies Public/Granted day:2019-12-26
Information query
